La chaîne d'options affiche les données clés des options sur actions de Eton Pharmaceuticals à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Eton Pharmaceuticals..

Eton Pharmaceuticals (NASDAQ:ETON) Stock, Chaîne d'Options

ETON PHARMACEUTICALS INC

Eton Pharmaceuticals

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.

Eton Pharmaceuticals, Inc. - Common Stock

Eton Pharmaceuticals Inc

Keefe, Bruyette &amp; Woods analyst Ryan Tomasello maintains Riskified (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSKD#NYSE">RSKD</a>) with a Market Perform and raises the price target from $5.25 to $5.5.

News

Price Target

Analyst Ratings

RSKD

Keefe, Bruyette & Woods Maintains Market Perform on Riskified, Raises Price Target to $5.5

RBC Capital analyst Daniel Perlin maintains DXC Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXC#NYSE">DXC</a>) with a Sector Perform and lowers the price target from $27 to $18.

RBC Capital Maintains Sector Perform on DXC Technology, Lowers Price Target to $18

Streaming giant Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) shared an impressive milestone for its<a href="https://www.benzinga.com/general/entertainment/25/04/44905838/netflix-playing-offense-while-stock-plays-defense-6-analysts-on-q1-results-advertising-growth-ahead"> ad-supported plan</a> at its upfront presentation to advertisers, along with highlighting upcoming content that includes bets on live content and reality television.
Ad-Supported Plan Shines: Fresh off its recent <a href="https://www.benzinga.com/general/entertainment/25/04/44877995/netflix-crushes-q1-says-its-working-hard-to-improve-and-expand-its-offering">quarterly financial results </a>that beat Street estimates, Netflix and its shareholders may have more reasons to celebrate.
The company announced its ad-supported plan, which launched in 2022, has hit 94 million monthly active users globally. This total is up from 70 million in November 2024, as reported by <a href="https://deadline.com/2025/05/netflix-ad-tier-reaches-94-million-monthly-active-users-1236397938/">Deadline</a>.
Netflix said its ad-supported plan users spend 41 hours watching Netflix content a month on average. Netflix's President of Advertising Amy Reinhard said the company's ad-supported plan reaches more people in the key 18-34 year-old demographic than any broadcast or cable network.
"When you compare us to our competitors, attention starts higher and ends much higher. And even more impressive, members pay as much attention to mid-roll ads as they do to the shows and movies themselves," Reinhard said.
The strong response to the ad-supported plan could be good news for the company with the launch of its in-house advertising platform in the U.S. and Canada. Netflix said it will roll this platform out in the remaining ad-supported countries by June.
Reinhart said Netflix's superpower is having great technology and great entertainment when rival streaming companies are usually "either/or."
"The foundation of our business is in place. From here, the pace of progress is going to be even faster."
Read Also: <a href="https://www.benzinga.com/general/entertainment/25/05/45200209/exclusive-netflix-customers-excited-for-original-movies-squid-game-stranger-things-nfl-60-say-this-tops-2025-must-watch-list">EXCLUSIVE: Netflix Customers Excited For Original Movies, &#8216;Squid Game,&#8217; &#8216;Stranger Things,&#8217; NFL: 60% Say This Tops 2025 Must-Watch List</a>
More Live Content/Reality TV: Netflix has been adding live content like sports, comedy specials and award shows in recent years in a push for more subscribers and additional advertising revenue.
At the upfront, Netflix Chief Content Officer Bela Bajaria highlighted some upcoming live content, such as a boxing match on July 11 and two NFL games on Christmas Day, as reported by <a href="https://techcrunch.com/2025/05/14/netflix-adds-more-live-tv-to-its-lineup/">TechCrunch</a>.
The NFL schedule was released Wednesday. The two Netflix Christmas games have been revealed as the Dallas Cowboys vs. Washington Commanders (1 p.m. ET) and the Detroit Lions vs. Minnesota Vikings (4:30 p.m. ET).
Netflix also announced it will livestream the Screen Actors Guild Awards on March 1, 2026 and stream its upcoming "Netflix Tudum 2025: The Live Event" on May 31, 2025.
The streaming company highlighted several upcoming reality competitions, including a reboot of "Star Search," an old talent show that aired from 1983 to 1995, as reported by <a href="https://deadline.com/2025/05/tar-search-reboot-underway-at-netflix-1236397644/">Deadline</a>.
Netflix's "Star Search" will see contestants perform in music, dance and comedy with kids also able to compete. Episodes will be livestreamed twice weekly with viewers voting on the contestants they like best to move forward in the competition.
The original "Star Search," with Ed McMahon as the host, featured many future celebrities before they were famous including Beyoncé, Justin Timberlake, Britney Spears, Dave Chappelle, Christina Aguilera and Adam Sandler.
A "Star Search" reboot in 2003 lasted only one year for CBS.
Netflix will also <a href="https://deadline.com/2025/05/building-the-band-premiere-window-netflix-liam-payne-1236398121/">debut </a>a new music reality competition called "Building the Band" this summer. The series, which has already been filmed, is the final TV series from late One Direction band member Liam Payne.
Payne was featured as one of the judges and mentors on the show alongside Nicole Scherzinger and Kelly Rowland, with Backstreet Boys member AJ McLean hosting.
The show was wrapped prior to Payne's death in October, but has been stuck in limbo with Netflix consulting with Payne's family on how to proceed with the show.
On the show, singers form bands without being able to see each other, in a format similar to "Love is Blind."
Why It's Important: While Netflix's upfront presentation was mostly a celebration of success and a look into future content for advertisers, it can likely be a key demonstration to shareholders of where the company is headed.
Advertising has become a key focus for the company to boost future revenue, and live content has shown success in capturing strong viewership and premium advertising rates.
Netflix has launched several reality TV competitions in the past and the ability to show off "Star Search" as a live competition with fan voting could put the streamer on par with broadcast network reality competitions that command premium audiences with live voting elements.
Along with new content, Netflix also announced renewals of several hit shows including "Bridgerton," "Love on the Spectrum" and "My Life with the Walter Boys."
Netflix has an exciting 2025 ahead, with new seasons of "Wednesday," "Stranger Things," and "Squid Game" all set to come, alongside new content and live sports content from WWE, boxing, and the NFL.
NFLX Price Action: Netflix stock is up 1.1% to $1,163.42 versus a 52-week trading range of $587.04 to $1,164.00. Netflix stock is up 31% year-to-date in 2025 and more than 80% over the last year.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/entertainment/25/03/44440954/netflix-announces-willy-wonka-inspired-reality-competition-with-a-golden-ticket-twist">Netflix Announces Willy Wonka-Inspired Reality Competition With A &#8216;Golden Ticket&#8217; Twist</a></li>
</ul>
Photo: Shutterstock

Entertainment

Trading Ideas

NFLX

Netflix's Ad-Tier Now Boasts 94M Users, Fueling Stock's Rise To Record Highs

<a href="https://www.globenewswire.com/Tracker?data=fpTh3m2aBO6q7tsA-PDh6eevm0wYq5BZbA8sB6ZdtrN6ym0dYw2DcX8IHhq5DInrHL5a5DBDXJISeSN2A5T-KRxJKwgvlE_gXv01SfKGsq0=">Coca-Cola Consolidated</a> is pleased to announce a $90 million investment in a new 400,000-square-foot distribution and warehouse facility, and two 15,000 square-feet buildings to house equipment repair services and fleet maintenance in Columbus, Ohio. The new 60-acre campus is part of the Rickenbacker Industrial Center located on Rohr Road. Through innovative sustainability processes, new technology, and designated learning center, the facility can better serve customers, the Columbus community and the surrounding region.

COKE

Coca-Cola Consolidated Announces $90M Investment In Columbus Facility

CSCO

Live On CNBC, Jim Lebenthal Announces Bought More Cisco Systems

Susquehanna analyst Biju Perincheril maintains NEXTracker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) with a Positive and raises the price target from $54 to $66.

Susquehanna Maintains Positive on NEXTracker, Raises Price Target to $66

XIAO-I (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIXI#NASDAQ">AIXI</a>) reported quarterly losses of $(0.56) per share. This is a 50 percent increase over losses of $(1.12) per share from the same period last year. The company reported $70.31 million in sales this quarter. This is a 18.84 percent increase over sales of $59.17 million the same period last year.

Earnings

AIXI

CORRECTION: XIAO-I FY EPS $(0.56) Up From $(1.12) YoY, Sales $70.31M Up From $59.17M YoY

California's cannabis industry was dealt a serious blow this week as Gov. Gavin Newsom's revised state budget confirmed the scheduled increase in the cannabis excise tax from 15% to 19%, effective July 1. The change, originally triggered by Assembly Bill 195 in 2022, will move forward despite calls from industry leaders and lawmakers to delay or freeze the hike amid ongoing market contraction and widespread business closures.
<h3 class="wp-block-heading">&#8216;A More Than 25% Tax Increase&#8217; On A Declining Market</h3>
The California Cannabis Operators Association (CaCOA), which represents over 300 licensed businesses across the state, warned the increase could be catastrophic.
"California's legal cannabis industry cannot withstand a more than 25% tax increase when sales have already declined by 19% and thousands of businesses have closed their doors," said Amy O'Gorman Jenkins, executive director of CaCOA. "Raising taxes on a struggling industry—especially one already undercut by untaxed, unregulated operators—defies economic sense and contradicts Proposition 64's core intent."
The tax bump stems from a 2022 policy change that eliminated California's cannabis cultivation tax and shifted revenue collection downstream to retail. Under that law, the excise tax rate was set to adjust based on revenue trends and the California Department of Tax and Fee Administration (CDTFA) announced in April that the rate would rise to 19% starting July 1, 2025.
The updated budget leaves the rate increase untouched. While it proposes tougher enforcement against illicit sellers and maintains licensing fee stability, it omits any relief for regulated operators facing rising costs and shrinking margins.
<h3 class="wp-block-heading">A Legislative Push To Freeze The Tax</h3>
Assemblymember Matt Haney (D-San Francisco) introduced AB 564 earlier this year to halt the tax hike. The bill passed early committee votes with bipartisan support, but time is running out. CaCOA says it's mobilizing with Haney and coalition partners to include the freeze in a trailer bill ahead of the final budget vote in June.
"This fight is far from over," CaCOA said in a statement. "We're working to ensure the freeze is included in the final budget through trailer bill legislation."
<h3 class="wp-block-heading">What It Means For Operators</h3>
The impact of the tax hike will be most visible at the cash register, where total taxes (state excise, sales tax and local levies) can already exceed 40% in many parts of California. Industry groups warn that such burdens will push more consumers toward unlicensed sellers, further eroding legal sales.
Companies like Glass House Brands (OTCQX:<a class="ticker" href="https://www.benzinga.com/stock/GLASF#OTCQX">GLASF</a>), one of the state's largest cannabis producers and retailers, have already expressed concern about pricing pressures. Though Glass House has managed to gain market share by lowering production costs, CEO Kyle Kazan recently noted that California pricing remains "destructive," forcing many competitors into insolvency.
Other publicly traded cannabis companies with significant exposure to California, such as Planet 13 Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/PLNH#OTC">PLNH</a>), StateHouse Holdings (OTC:<a class="ticker" href="https://www.benzinga.com/stock/STHZF#OTC">STHZF</a>) and Gold Flora Corporation (OTC:<a class="ticker" href="https://www.benzinga.com/stock/GRAM#OTC">GRAM</a>), are navigating substantial financial challenges. Planet 13 remains operational, reporting revenue growth in its latest quarterly results. In contrast, StateHouse Holdings filed for bankruptcy in Canada in October 2024 and entered receivership proceedings in the U.S., with operations continuing under court supervision. Similarly, Gold Flora filed for voluntary receivership in March 2025 due to mounting debts and legal issues, including liabilities inherited from its 2023 merger with TPCO. Despite these proceedings, Gold Flora continues to operate its 16 dispensaries and cultivation facilities while preparing for an orderly sale of its assets. The impending excise tax hike may further complicate efforts for these companies to maintain market share and achieve profitability.
<h3 class="wp-block-heading">Budget Highlights: Enforcement, But No Relief</h3>
The revised budget does include proposals to expand enforcement powers for the Department of Cannabis Control (DCC), including authority to seal unlicensed businesses—similar to New York's "Operation Padlock to Protect." It also provides funding incentives for cities and counties to allow cannabis retail, even if they currently prohibit cultivation.
Still, those measures fall short of what many in the industry say is necessary to stabilize the market.
Photo: Shutterstock

Cannabis

Government

Regulations

Politics

GLASF

GRAM

PLNH

STEEL AND TUBE HLDGS LTD by Steel and Tube Holdings Ltd

STHZF

Gavin Newsom's Budget Keeps Cannabis Tax Hike: Can It Be Stopped? What's Next For Operators?

Susquehanna analyst Shyam Patil maintains JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) with a Neutral and lowers the price target from $45 to $40.

Susquehanna Maintains Neutral on JD.com, Lowers Price Target to $40

<a href="https://www.gov.uk/government/news/mhra-approves-vaccine-to-protect-against-pneumococcal-infections-such-as-pneumonia-and-meningitis#:~:text=The%20Medicines%20and%20Healthcare%20products,called%20Streptococcus%20pneumoniae%20or%20pneumococcus" title="https://www.gov.uk/government/news/mhra-approves-vaccine-to-protect-against-pneumococcal-infections-such-as-pneumonia-and-meningitis#:~:text=The%20Medicines%20and%20Healthcare%20products,called%20Streptococcus%20pneumoniae%20or%20pneumococcus">https://www.gov.uk/government/news/mhra-approves-vaccine-to-protect-against-pneumococcal-infections-such-as-pneumonia-and-meningitis#:~:text=The%20Medicines%20and%20Healthcare%20products,called%20Streptococcus%20pneumoniae%20or%20pneumococcus</a>.

Biotech

Global

General

MHRA Approves Vaccine To Protect Against Pneumococcal Infections Such As Pneumonia And Meningitis; Approved Capvaxive For People Aged 18 Years & Older To Help Protect Against Pneumococcal Infections

RBC Capital analyst Brian Abrahams reiterates Contineum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNM#NASDAQ">CTNM</a>) with a Outperform and maintains $31 price target.

Reiteration

CTNM

RBC Capital Reiterates Outperform on Contineum Therapeutics, Maintains $31 Price Target

WIIM

Galiano Gold shares are trading lower after the company reported mixed Q1 financial results.

Shares of Chinese EV maker NIO Inc &#8211; ADR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) fell around 3% to $4.00 on Thursday, tracking broader weakness in U.S.-listed Chinese stocks after Alibaba Group reported mixed fiscal fourth-quarter results. Alibaba shares dropped 8.1% to $123.05 after <a href="https://www.benzinga.com/news/earnings/25/05/45437447/alibaba-stock-slides-5-after-revenue-miss-cloud-spend-hits-free-cash-flow">missing revenue expectations</a>, despite beating earnings estimates.
What To Know: Alibaba posted $32.58 billion in quarterly revenue, falling short of the $33.08 billion analyst consensus. Although adjusted earnings per ADS came in strong at $1.73 versus estimates of $1.48, the topline miss and deceleration in some key business segments weighed on investor sentiment.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45442180/whats-going-on-with-ericsson-stock-on-thursday">What&#8217;s Going On With Ericsson Stock On Thursday?</a>
In particular, declines in <a href="https://www.benzinga.com/news/earnings/25/05/45437447/alibaba-stock-slides-5-after-revenue-miss-cloud-spend-hits-free-cash-flow">logistics revenue</a> and planned pullbacks in direct sales raised concerns about broader macro and consumer demand trends in China.

Why It Matters: As a China-based growth stock, Nio is often viewed in tandem with other major Chinese firms like Alibaba. When a heavyweight like Alibaba underperforms or signals broader economic uncertainty, it tends to trigger sympathy selling across U.S.-listed Chinese equities, especially those tied to consumer demand and domestic growth.
Read Also: <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45435725/tariffs-slow-retail-spending-as-producer-prices-post-sharpest-drop-since-2020">Tariffs Slow Retail Spending As Producer Prices Post Sharpest Drop Since 2020</a>
<h2 class="wp-block-heading">How To Buy NIO Stock</h2>
By now you're likely curious about how to participate in the market for NIO &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of NIO, which is trading at $4.0 as of publishing time, $100 would buy you 25.0 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, NIO has a 52-week high of $7.71 and a 52-week low of $3.02.

NIO Stock Is Sliding Thursday: What's Going On?

<ul>
<li>Biofrontera has received patent approval for the revised formulation of Ameluz&#xAE;, which extends patent protection through to December 2043</li>
<li>Ameluz PDT offers the potential for effective treatment of moderate to severe acne without the side effects associated with some systemic therapies4</li>
<li>Approximately 50 million people in the US are suffering from acne vulgaris, including both adolescents and adults1,2</li>
<li>The US acne treatment market was valued at $5.7 billion in 2024 and is growing annually5</li>
</ul>
WOBURN, Mass., May 15, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>), a biopharmaceutical company focused on the development and commercialization of photodynamic therapy (PDT), received confirmation that the updated formulation of the Ameluz&#xAE; nanoemulsion gel without propylene glycol received patent approval through to December 2043. The formulation was earlier accepted for use in Ameluz&#xAE; by the US Food and Drug Administration (FDA) and is in use since 2024. In addition to this long-lasting protection of Ameluz&#xAE; against generic competition, Biofrontera today announced the successful enrollment of the final patient in its Phase 2b clinical trial evaluating Ameluz&#xAE; (aminolevulinic acid hydrochloride) for the treatment of moderate to severe acne vulgaris.

BFRI

Biofrontera Receives Patent Approval For Updated Formulation Of Ameluz Nanoemulsion Gel Without Propylene Glycol, Through To December 2043

Susquehanna analyst James Friedman maintains DLocal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DLO#NASDAQ">DLO</a>) with a Positive and raises the price target from $16 to $18.

Susquehanna Maintains Positive on DLocal, Raises Price Target to $18

WBTN

WEBTOON Entertainment shares are trading higher after Citigroup initiated coverage on the stock with a Buy rating and announced an $11 price target.

Susquehanna analyst Christopher Stathoulopoulos maintains Hertz Global Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) with a Neutral and raises the price target from $4.45 to $5.

Susquehanna Maintains Neutral on Hertz Global Holdings, Raises Price Target to $5

From despair to euphoria in record time, <a href="https://www.benzinga.com/topic/s-p-500">the S&amp;P 500</a> has pulled off a historic U-turn, rallying 22% from its April 7 lows to turn green on the year.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0515"><img loading="lazy" decoding="async" width="633" height="488" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15105908/Screenshot-2025-05-15-at-8.26.50-PM.png" alt="" class="wp-image-916749" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15105908/Screenshot-2025-05-15-at-8.26.50-PM.png 633w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15105908/Screenshot-2025-05-15-at-8.26.50-PM-300x231.png 300w" sizes="(max-width: 633px) 100vw, 633px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0515" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Charlie Bilello, founder of Compound Capital Advisors, <a href="https://x.com/charliebilello/status/1922302125024923719?s=31">called it</a> &#8220;one of the biggest short-term comebacks in market history.&#8221; And it's not just an index story &#8211; ETF investors in SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), the iShares Core S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVV#NYSE">IVV</a>) and the Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) are riding the same wave.
<h2 class="wp-block-heading">Trade Truce Sparks Turbocharged Turnaround</h2>
What triggered the rip? 
A sudden thaw in U.S.-China trade tensions. Tariff threats that had markets rattled just weeks ago were slashed: the U.S. <a href="https://www.benzinga.com/government/regulations/25/05/45348699/us-listed-chinese-stocks-rally-as-countries-agree-to-ease-import-tariffs">cut its rate on Chinese goods</a> from 145% to 30%, and China blinked right back &#8211; lowering its retaliatory tariffs from 125% to 10%. Global markets exhaled, and stocks took flight.
Read Also: <a href="https://www.benzinga.com/25/05/45442127/palantir-soars-500-in-a-year-while-unitedhealth-tanks-40-tech-leaves-healthcare-in-the-dust">Palantir Soars 500% In A Year While UnitedHealth Tanks 40% — Tech Leaves Healthcare In The Dust</a>
<h2 class="wp-block-heading">SPY Has A Classic Bullish Setup</h2>
Technically, SPY is lighting up every bullish signal on the board. At $586.53, SPY trades well above its eight-day simple moving average (SMA) of $574.16, its 20-day SMA of $557.10, and its 50-day SMA of $553.63. Even the 200-day SMA at $574.12 trails the price &#8211; classic bullish setup.
Momentum-wise, the Moving Average Convergence Divergence (MACD) sits at a strong 9.81, while the Relative Strength Index (RSI) reads 65.95, just shy of overbought territory but still flashing strength.
For holders of SPY, IVV, and VOO, the message is clear: the market isn't just bouncing &#8211; it's sprinting. The comeback has put passive investors back in the green, with technicals suggesting the rally could have more room to run.
Just weeks ago, this market looked cornered. Now, it's rewriting the rebound playbook.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45435170/jim-cramer-says-this-will-hurt-apple-president-trump-making-it-tough">Jim Cramer Says This &#8216;Will Hurt&#8217; Apple: &#8216;President Trump Making It Tough&#8230;</a></li>
</ul>
Image: Shutterstock

Analyst Color

Broad U.S. Equity ETFs

Technicals

ETFs

Rout To Rally: S&P 500 Stages Fastest Flip In Market History With 22% Comeback

Avino Silver & Gold Mines shares are trading higher after HC Wainwright raised its price target on the stock from $2.2 to $2.8.

Piper Sandler analyst James Fish maintains Cisco Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) with a Neutral and raises the price target from $60 to $64.

Comments

Eton Pharmaceuticals

Eton Pharmaceuticals (ETON) Options

Loading...

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL